Alembic Pharmaceuticals shares jumped more than 3% in morning trade after the US Food and Drug Administration (USFDA) granted final approval for its Abbreviated New Drug Application (ANDA) for Lamotrigine Extended-Release Tablets USP in 200 mg, 250 mg, and 300 mg strengths.
These tablets are the therapeutic equivalent of GlaxoSmithKline’s Lamictal XR and are meant for the treatment of seizures in patients aged 13 and older.
As of 10:57 am, Alembic Pharmaceuticals shares were trading 2.52% higher at Rs 1,222.00 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
